<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01173978</url>
  </required_header>
  <id_info>
    <org_study_id>DYS-CLAMP</org_study_id>
    <nct_id>NCT01173978</nct_id>
  </id_info>
  <brief_title>Insulinotropic Effect of GIP and GLP-1 Before and After Reduced Glucose Tolerance</brief_title>
  <official_title>Insulinotropic Effect of GIP and GLP-1 Before and After Reduced Glucose Induced by Steroid Treatment, Relative Physical Inactivity and High Calorie Diet</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glostrup University Hospital, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Foundation for the Study of Diabetes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Glostrup University Hospital, Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The incretin effect in patients with type two diabetes is reduced. The investigators have
      previously shown that it is possible to induce a defect in the incretin effect in healthy
      individuals. The purpose of this study is to evaluate the insulinotropic affect of the
      incretin hormones in healthy individuals before and after a deterioration of the glucose
      homeostasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The incretin effect in patients with type two diabetes is reduced. The investigators have
      previously shown that it is possible to induce a defect in the incretin effect in healthy
      individuals. The purpose of this study is to evaluate the insulinotropic affect of the
      incretin hormones in healthy individuals before and after a deterioration of the glucose
      homeostasis. The evaluation is done by infusing GIP, GLP-1 or saline during hyperglycemic
      clamps.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulinotropic effect of incretin hormones</measure>
    <time_frame>12 days</time_frame>
    <description>Measurements of the insulinotropic effect of incretin hormones before and after 12 days intervention with steroid treatment, high calorie diet and relative physical inactivity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of glucagon</measure>
    <time_frame>12 days</time_frame>
    <description>Measurements of plasma concentration of glucagon before and after 12 days intervention with steroid treatment, high calorie diet and relative physical inactivity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Insulin Resistance</condition>
  <condition>Deteriorated Glucose Homeostasis</condition>
  <condition>Inactivity</condition>
  <arm_group>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each participant is examined during a normal, active lifestyle, without any intervention: The examinations include an OGTT, a glucagon test, three hyperglycemic clamps with infusion of a)GLP-1; b)GIP; c)Nacl</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each participant is examined during a 12 days intervention.The examinations include an OGTT, a glucagon test, three hyperglycemic clamps with infusion of a)GLP-1; b)GIP; c)Nacl</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Steroid hormone</intervention_name>
    <description>Steroid hormone: 37,5 mg of prednisolone; High energy diet: 130 % of recommended daily energy intake; Relative physical inactivity: no exercise and at least 8 hours of rest/day</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Prednisolone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <arm_group_label>No intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Caucasians without type 2 diabetes mellitus

          -  Normal OGTT (75 g of glucose) according to WHO's criteria

          -  BMI 20-30

          -  Hemoglobin &gt; 8.0 mmol/l

          -  Informed consent

        Exclusion Criteria:

          -  Liver disease (ALAT &gt; 2 x normal level)

          -  Nephropathy (s-creatinin &gt; 130 µM or albuminuria)

          -  Relatives (parents/siblings) with T2DM

          -  Medical treatment witch cannot be stopped for 12 hours
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katrine B Hansen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Glostrup University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Filip K Knop, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Gentofte University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tina Vilsbøll, MD,DmSc</last_name>
    <role>Study Chair</role>
    <affiliation>Gentofte University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jens J Holst, MD, DmSc</last_name>
    <role>Study Chair</role>
    <affiliation>University of Copenhagen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Clinical Physiology</name>
      <address>
        <city>Glostrup</city>
        <zip>DK-2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2010</study_first_submitted>
  <study_first_submitted_qc>August 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2010</study_first_posted>
  <last_update_submitted>June 20, 2011</last_update_submitted>
  <last_update_submitted_qc>June 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2011</last_update_posted>
  <responsible_party>
    <name_title>Katrine Bagge Hansen. MD</name_title>
    <organization>Glostrup University Hospital</organization>
  </responsible_party>
  <keyword>Incretin hormones</keyword>
  <keyword>Glucagon</keyword>
  <keyword>Insulin/c-peptide</keyword>
  <keyword>Plasma glucose</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Deteriorated glucose homeostasis</keyword>
  <keyword>Inactivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

